Exclusion of HIV coreceptors CXCR4, CCR5, and CCR3 from the HIV envelope.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Exclusion of HIV coreceptors CXCR4, CCR5, and CCR3 from the HIV envelope.

AIDS Res Hum Retroviruses. 1999 Jul 1;15(10):895-7. Unique Identifier : AIDSLINE MED/99335211
Lallos LB; Laal S; Hoxie JA; Zolla-Pazner S; Bandres JC; Research Center for AIDS and HIV Infection, Manhattan VA Medical; Center, New York University Medical School, New York 10010, USA.

Abstract: Both HIV-1 primary isolates and laboratory strains incorporate cell-derived molecules into their envelopes depending on the host cell in which they are grown. This incorporation is not random and, specifically, HIV-1 has been shown to select against the incorporation into its surface of CD4, its main receptor. In this study, we have looked at the incorporation of HIV coreceptors CXCR4, CCR5, and CCR3 into the HIV envelope. For this purpose, we grew HIV-1 primary isolate BZ167 in several cell lines and PBMCs, and the envelope profiles of the resulting viruses were determined with a virus-binding ELISA. While the virus particle gained several molecules when passed through the different cell lines (e.g., ICAM-3, LFA-1, ICAM-1, or MHC class II), BZ167 never incorporated significant levels of CXCR4, CCR5, or CCR3 into its envelope even though some or all of the cell lines in which it was grown expressed them. These results show that HIV-1 selects against the incorporation of these chemokine receptors into its envelope molecule, as it does against the incorporation of CD4.

Keywords: JOURNAL ARTICLE Cell Line Human HIV Envelope Protein gp120/*METABOLISM HIV-1/*METABOLISM Peptide Fragments/*METABOLISM Receptors, Chemokine/*METABOLISM Receptors, CCR5/*METABOLISM Receptors, CXCR4/*METABOLISM Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S.
991130
A99B1084

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .